The discovery of nuclear receptors and transporters has contributed to the development of
new drugs for the treatment of cholestatic liver diseases. Particular progress has been made …

Autoimmune liver diseases (AILDs) include autoimmune hepatitis, primary biliary cholangitis
and primary sclerosing cholangitis. The etiologies of AILD are not well understood but …

Seladelpar efficacy and safety at 3 months in patients with... : Hepatology Seladelpar
efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a …

Background & Aims Recurrence of primary biliary cholangitis (PBC) after liver
transplantation (LT) is frequent and can impair graft and patient survival. Ursodeoxycholic …

PBC is a chronic progressive autoimmune disorder involving the destruction of intrahepatic
small bile ducts, cholestasis, fibrosis, and ultimately cirrhosis if left untreated. It is largely …

Background Seladelpar is a potent and selective peroxisome proliferator‐activated receptor‐
δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading …

Autoimmune liver diseases are characterized by immune-mediated inflammation and
eventual destruction of the hepatocytes and the biliary epithelial cells. They can progress to …

Autoimmune liver diseases (ALDs), including autoimmune hepatitis (AIH), primary
sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC), are an indication for liver …

The microbiome plays a crucial role in integrating environmental factors into host
physiology, potentially linking it to autoimmune liver diseases, such as autoimmune …

Autoimmune liver diseases (AILDs) are a group of conditions where immune-mediated liver
damage can lead to the need for transplantation. Collectively, they account for almost a …